Lutein & zeaxanthin
Demonstrated antioxidant and anti-inflammatory effects, protecting against photo-oxidative damage5
reduction in positive
MMP-9 tests1*†
increase in Schirmer test
score, which indicated an
increase in tear volume1*†
reduction in OSDI score
at day 561*†
improvement in tear
film stability2*†
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
†Based on results at Day 56 from a prospective, randomized, double-blind, parallel, placebo-controlled clinical study to evaluate the efficacy of NutriTears® in adults with dry eye symptoms.

Demonstrated antioxidant and anti-inflammatory effects, protecting against photo-oxidative damage5

Reduced pro-inflammatory cytokines in corneal epithelial cells in vitro6,7

Improved the efficacy of artificial tears and reduced symptom severity in both vitamin D3-deficient and non-deficient patients6,8-10
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
§Based on a clinical trial; N=116, randomized 1:1 NutriTears® and placebo.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

REFERENCES: 1. Gioia N, Gerson J, Ryan R, et al. A novel multi-ingredient supplement significantly improves ocular symptom severity and tear production in patients with dry eye disease: results from a randomized, placebo-controlled clinical trial. Front Ophthalmol. 2024;4:1362113. 2. OmniActive Health Technologies. Efficacy of NutriTears® in adult subjects with dry eye syndrome (DES). OmniActive Health Technologies. 2023. 3. Radkar P, Lakshmanan PS, Mary JJ, et al. A novel multi-ingredient supplement reduces inflammation of the eye and improves production and quality of tears in humans. Ophthalmol Ther. 2021;10(3):581–599. 4. Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289-386. 5. Cristaldi M, Anfuso CD, Spampinato G, et al. Comparative efficiency of lutein and astaxanthin in the protection of human corneal epithelial cells in vitro from blue-violet light photo-oxidative damage. Appl Sci. 2022;12(3):1268. 6. Castro-Castaneda CR, Altamirano-Lamarque F, Ortega-Macías AG, et al. Nutraceuticals: A promising therapeutic approach in ophthalmology. Nutrients. 2022;14(23):5014. 7. Najjaran M, Zarei-Ghanavati S, Arjmand Askari E, Eslampoor A, Ziaei M. Effect of oral vitamin D supplementation on dry eye disease patients with vitamin D deficiency. Clin Exp Optom. 2022;106(3):257-262. 7. Davis BM, Pahlitzsch M, Guo L, et al. Topical curcumin nanocarriers are neuroprotective in eye disease. Sci Rep. 2018;8(1):11066. 8. Gorimanipalli B, Khamar P, Sethu S, Shetty R. Hormones and dry eye disease. Indian J Ophthalmol. 2023;71(4):1276-1284. 9. Hwang JS, Lee YP, Shin YJ. Vitamin D enhances the efficacy of topical artificial tears in patients with dry eye disease. Cornea. Cornea. 2019;38(3):304-310. 10. Najjaran M, Zarei-Ghanavati S, Arjmand Askari E, Eslampoor A, Ziaei M. Effect of oral vitamin D supplementation on dry eye disease patients with vitamin D deficiency. Clin Exp Optom. 2023;106(3):257-262.